Expanded access programmes: Patient interests versus clinical trial integrity

Paul Lorigan; Paolo A. Ascierto; Reinhard Dummer; Alexander M. Eggermont; Keith T. Flaherty; Claus Garbe; Helen Gogas; Axel Hauschild; Richard F. Kefford; John M. Kirkwood; James Larkin; Georgina V. Long; Michele Maio; Grant A. McArthur; Antoni Ribas; Caroline Robert; Dirk Schadendorf; Vernon K. Sondak; Jedd D. Wolchok; Andrew M. Hudson

doi:10.1016/S1470-2045(14)71161-1

Expanded access programmes: Patient interests versus clinical trial integrity

Paul Lorigan, Paolo A. Ascierto, Reinhard Dummer, Alexander M. Eggermont, Keith T. Flaherty, Claus Garbe, Helen Gogas, Axel Hauschild, Richard F. Kefford, John M. Kirkwood, James Larkin, Georgina V. Long, Michele Maio, Grant A. McArthur, Antoni Ribas, Caroline Robert, Dirk Schadendorf, Vernon K. Sondak, Jedd D. Wolchok, Andrew M. Hudson

Onderzoeksoutput: Bijdrage aan tijdschrift › Opmerking/debat

8 Citaten (Scopus)

Originele taal-2	Engels
Pagina's (van-tot)	15-17
Aantal pagina's	3
Tijdschrift	The Lancet Oncology
Volume	16
Nummer van het tijdschrift	1
DOI's	https://doi.org/10.1016/S1470-2045(14)71161-1
Status	Gepubliceerd - 2015
Extern gepubliceerd	Ja

Toegang tot document

10.1016/S1470-2045(14)71161-1

Citeer dit

Lorigan, P., Ascierto, P. A., Dummer, R., Eggermont, A. M., Flaherty, K. T., Garbe, C., Gogas, H., Hauschild, A., Kefford, R. F., Kirkwood, J. M., Larkin, J., Long, G. V., Maio, M., McArthur, G. A., Ribas, A., Robert, C., Schadendorf, D., Sondak, V. K., Wolchok, J. D., & Hudson, A. M. (2015). Expanded access programmes: Patient interests versus clinical trial integrity. The Lancet Oncology, 16(1), 15-17. https://doi.org/10.1016/S1470-2045(14)71161-1

@article{505cb0f9662f404b87f5eafb700c207f,

title = "Expanded access programmes: Patient interests versus clinical trial integrity",

author = "Paul Lorigan and Ascierto, {Paolo A.} and Reinhard Dummer and Eggermont, {Alexander M.} and Flaherty, {Keith T.} and Claus Garbe and Helen Gogas and Axel Hauschild and Kefford, {Richard F.} and Kirkwood, {John M.} and James Larkin and Long, {Georgina V.} and Michele Maio and McArthur, {Grant A.} and Antoni Ribas and Caroline Robert and Dirk Schadendorf and Sondak, {Vernon K.} and Wolchok, {Jedd D.} and Hudson, {Andrew M.}",

note = "Funding Information: PL declares personal fees from Bristol Myers Squibb (BMS), Merck Sharp anf Dohme (Merck), GlaxoSmithKline, Roche, Novartis, Amgen, and Celgene outside the submitted work. PAA declares grants and personal fees from BMS, Roche Genentech, Ventana; personal fees and non-financial support from Merck, GlaxoSmithKline, Amgen and Novartis, all outside the submitted work. RD declares personal fees from Amgen, MSD, Novartis, grants and personal fees from BMS, Roche, outside the submitted work. AME reports personal fees from BMS, Merck, GlaxoSmithKline, MedImmune, outside the submitted work. KTF declares personal fees from GlaxoSmithKline, Roche, Novartis, and Merck all outside the submitted work. CG reports personal fees from Amgen, MSD, and Novartis, grants and personal fees from BMS, GlaxoSmithKline, Roche, outside the submitted work. HG reports personal fees from ROCHE, BMS, GlaxoSmithKline, MERCK, AMGEN, Novartis, outside the submitted work. AH reports personal fees for consultancies and presentations from Amgen, BMS, Celgene, Eisai, GlaxoSmithKline, MedImmune, Merck Serono, MSD/Merck, Novartis, Oncosec, Roche Pharma, outside the submitted work. RFK reports institutional reimbursement from GlaxoSmithKline, Merck, BMS, Novartis and Roche for Advisory Boards, and institutional reimbursement from BMS for an educational grant all outside the submitted work. JMK reports grants from Prometheus, personal fees from BMS, Merck, and GlaxoSmithKline outside the submitted work. JL reports grants from Pfizer, Novartis, BMS, MSD, outside the submitted work. GVL reports personal fees from GlaxoSmithKline, Roche, Novartis, BMS, Amgen, Merck, for advisory board and steering committee participation, outside the submitted work. MM reports grants and personal fees from BMS, ROCHE, GlaxoSmithKline, MedImmune, outside the submitted work. GAM reports grants from Pfizer Celgene, outside the submitted work and personal fees from Provectus. AR reports fees for consulting with Amgen, Astellas, Genentech-Roche, GlaxoSmithKline, Merck, Novartis, Pierre Fabre with honoraria deposited into a UCLA account, and Stock ownership in Compugen, Flexus Bio and Kite Pharma. CR declares personal fees from Amgen, BMS, Novartis, Merck, Roche, and GlaxoSmithKline for occasional consulting activities, outside the submitted work. DS reports personal fees for consultancies and presentations from Amgen, BMS, GlaxoSmithKline, MSD/Merck, Novartis, Roche and Boehringer Ingelheim, outside the submitted work. VKS reports personal fees from Merck, Amgen, OncoSec, MabVax, Polynoma, Bristol-Myers Squibb, and GlaxoSmithKline, outside the submitted work. JDW reports personal consulting fees from Bristol-Myers Squibb, Merck and Medimmune and institutional grants from Bristol-Myers Squibb, Medimmune and GlaxoSmithKline. All are unrelated to the submitted work. AMH declares no competing interests.",

year = "2015",

doi = "10.1016/S1470-2045(14)71161-1",

language = "English",

volume = "16",

pages = "15--17",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "1",

}

Lorigan, P, Ascierto, PA, Dummer, R, Eggermont, AM, Flaherty, KT, Garbe, C, Gogas, H, Hauschild, A, Kefford, RF, Kirkwood, JM, Larkin, J, Long, GV, Maio, M, McArthur, GA, Ribas, A, Robert, C, Schadendorf, D, Sondak, VK, Wolchok, JD & Hudson, AM 2015, 'Expanded access programmes: Patient interests versus clinical trial integrity', The Lancet Oncology, vol. 16, nr. 1, blz. 15-17. https://doi.org/10.1016/S1470-2045(14)71161-1

TY - JOUR

T1 - Expanded access programmes

T2 - Patient interests versus clinical trial integrity

AU - Lorigan, Paul

AU - Ascierto, Paolo A.

AU - Dummer, Reinhard

AU - Eggermont, Alexander M.

AU - Flaherty, Keith T.

AU - Garbe, Claus

AU - Gogas, Helen

AU - Hauschild, Axel

AU - Kefford, Richard F.

AU - Kirkwood, John M.

AU - Larkin, James

AU - Long, Georgina V.

AU - Maio, Michele

AU - McArthur, Grant A.

AU - Ribas, Antoni

AU - Robert, Caroline

AU - Schadendorf, Dirk

AU - Sondak, Vernon K.

AU - Wolchok, Jedd D.

AU - Hudson, Andrew M.

N1 - Funding Information: PL declares personal fees from Bristol Myers Squibb (BMS), Merck Sharp anf Dohme (Merck), GlaxoSmithKline, Roche, Novartis, Amgen, and Celgene outside the submitted work. PAA declares grants and personal fees from BMS, Roche Genentech, Ventana; personal fees and non-financial support from Merck, GlaxoSmithKline, Amgen and Novartis, all outside the submitted work. RD declares personal fees from Amgen, MSD, Novartis, grants and personal fees from BMS, Roche, outside the submitted work. AME reports personal fees from BMS, Merck, GlaxoSmithKline, MedImmune, outside the submitted work. KTF declares personal fees from GlaxoSmithKline, Roche, Novartis, and Merck all outside the submitted work. CG reports personal fees from Amgen, MSD, and Novartis, grants and personal fees from BMS, GlaxoSmithKline, Roche, outside the submitted work. HG reports personal fees from ROCHE, BMS, GlaxoSmithKline, MERCK, AMGEN, Novartis, outside the submitted work. AH reports personal fees for consultancies and presentations from Amgen, BMS, Celgene, Eisai, GlaxoSmithKline, MedImmune, Merck Serono, MSD/Merck, Novartis, Oncosec, Roche Pharma, outside the submitted work. RFK reports institutional reimbursement from GlaxoSmithKline, Merck, BMS, Novartis and Roche for Advisory Boards, and institutional reimbursement from BMS for an educational grant all outside the submitted work. JMK reports grants from Prometheus, personal fees from BMS, Merck, and GlaxoSmithKline outside the submitted work. JL reports grants from Pfizer, Novartis, BMS, MSD, outside the submitted work. GVL reports personal fees from GlaxoSmithKline, Roche, Novartis, BMS, Amgen, Merck, for advisory board and steering committee participation, outside the submitted work. MM reports grants and personal fees from BMS, ROCHE, GlaxoSmithKline, MedImmune, outside the submitted work. GAM reports grants from Pfizer Celgene, outside the submitted work and personal fees from Provectus. AR reports fees for consulting with Amgen, Astellas, Genentech-Roche, GlaxoSmithKline, Merck, Novartis, Pierre Fabre with honoraria deposited into a UCLA account, and Stock ownership in Compugen, Flexus Bio and Kite Pharma. CR declares personal fees from Amgen, BMS, Novartis, Merck, Roche, and GlaxoSmithKline for occasional consulting activities, outside the submitted work. DS reports personal fees for consultancies and presentations from Amgen, BMS, GlaxoSmithKline, MSD/Merck, Novartis, Roche and Boehringer Ingelheim, outside the submitted work. VKS reports personal fees from Merck, Amgen, OncoSec, MabVax, Polynoma, Bristol-Myers Squibb, and GlaxoSmithKline, outside the submitted work. JDW reports personal consulting fees from Bristol-Myers Squibb, Merck and Medimmune and institutional grants from Bristol-Myers Squibb, Medimmune and GlaxoSmithKline. All are unrelated to the submitted work. AMH declares no competing interests.

PY - 2015

Y1 - 2015

UR - http://www.scopus.com/inward/record.url?scp=84927635228&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(14)71161-1

DO - 10.1016/S1470-2045(14)71161-1

M3 - Comment/debate

C2 - 25638540

AN - SCOPUS:84927635228

SN - 1470-2045

VL - 16

SP - 15

EP - 17

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 1

ER -